Navigation Links
China YCT International Group, Inc. Announces That the State Intellectual Property Office of the People's Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
Date:1/25/2010

SHANDONG, China, Jan. 25 /PRNewswire-Asia-FirstCall/ -- China YCT International Group, Inc. ("China YCT" or the "Company") (OTC Bulletin Board: CYIG) today announced that on December 23, 2009 the State Intellectual Property Office of the People's Republic of China approved the patent application of its operating subsidiary, Shandong Spring Pharmaceutical Co., Ltd., for "a unique method of making ginkgo tea, and the manufacturing technology." This patent represents a key addition to the Company's growing intellectual property portfolio.

China YCT's technology improves the methods traditionally employed in the gingko tea health care products industry, and provides a faster, more efficient method of offering the public gingko tea. Studies have shown that Gingko tea has memory-enhancing benefits for people. "Our method of producing gingko tea increases the memory-enhancing ingredients as compared to the traditional gingko products, so our products will provide increased resistance to memory loss, whether short- or long-term," said Mr. Tinghe Yan, Chairman and CEO of China YCT.

The Company's new products can slow down the platelet activating factor (PAF) to stop it from over stimulation. Medical studies have shown that excess production of PAF can result in various inflammation-related diseases, including damage to the brain. In addition, like all other properly made gingko tea products, the Company's new products help reduce cholesterol and aid in blood circulation, thus reducing the risk of heart disease.

In order to maximize the benefits of gingko, the Company's R&D team developed a new and unique production method. "Our unique new gingko tea products, which will provide many physical benefits to people that other gingko teas cannot, give us confidence that we can make successful inroads into China's healthcare market in the years ahead," said Mr. Tinghe Yan.

"Receiving this patent is another important milestone, as China YCT accelerates its strategic growth plan," said Mr. Yan. "We're committed to developing innovative products based on our experience in the gingko healthcare products industry. We intend this to be the first in a series of technological breakthroughs, and we will continue to seek legal protection for these innovations. The benefits of our new products enhance the value of the Company as a whole," Mr. Yan added.

About China YCT International Group, Inc.

Established in 2005, China YCT International Group, Inc., through its operating subsidiary, Shandong Spring Pharmaceutical Co. Ltd., a corporation organized under the laws of the People's Republic of China, is a high-tech enterprise, which applies modern biological technology and integrates research & development, production and sales of ginkgo healthcare products, ginkgo cosmetics, daily-use chemical products, ginkgo glycoside products and biological medicines.

Safe Harbor Statement

The statements contained herein that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should" or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors described from time to time in our filings with the Securities and Exchange Commission under the heading "Risk Factors" could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this press release, and we undertake no obligation to publicly update such forward- looking statements to reflect subsequent events or circumstances.

    For further information, contact:

     Zecheng Shao
     Phone: +86-537-426-8260
     Fax:   +86-537-426-8292

SOURCE China YCT International Group, Inc.


'/>"/>
SOURCE China YCT International Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
2. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
3. China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option
4. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
5. American Oriental Bioengineering Announces the Inclusion of 158 Drugs in Chinas National Insurance Catalog
6. China Sky Medical, Inc. Has 30 Medicines that will Be Included in Chinas National Insurance Directory
7. China Biologic Products to Ring NASDAQ Opening Bell
8. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
9. Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit
10. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
11. China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), ... and plans to commercialize innovative therapeutics for patients ... stock were approved for trading on the OTCQX ... the OTCQX, effective today, under the ticker symbol ... market, companies must meet high financial standards, follow ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... McLean, VA (PRWEB) , ... December 07, 2016 ... ... peer-reviewed medical journal has concluded that “in the setting of previously treated, advanced ... Further refinement in defining the optimal patient population and timing of blood sampling ...
Breaking Biology Technology:
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
Breaking Biology News(10 mins):